Morgan Joseph Starts Pernix Therapeutics (PTX) at Buy; Profitability and Sustainable Cash Flows
Tweet
Share
E-mailGet Alerts PTX Hot Sheet
Price: $0.21 --0%
Rating Summary:
4 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 20
Rating Summary:
4 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 20
Join SI Premium – FREE
Morgan Joseph initiates coverage on Pernix Therapeutics (NYSE: PTX) with a Buy. PT $28.
Morgan analyst says, "Pernix has been reliably profitable since its debut as a publicly-traded entity, and we believe sales are likely to grow significantly during allergy season. We are forecasting net income of $7.4mm in 2011, growing to $22.3mm in 2012."
For more ratings news on Pernix Therapeutics click here and for the rating history of Pernix Therapeutics click here.
Shares of Pernix Therapeutics closed at $8.30 yesterday.
Morgan analyst says, "Pernix has been reliably profitable since its debut as a publicly-traded entity, and we believe sales are likely to grow significantly during allergy season. We are forecasting net income of $7.4mm in 2011, growing to $22.3mm in 2012."
For more ratings news on Pernix Therapeutics click here and for the rating history of Pernix Therapeutics click here.
Shares of Pernix Therapeutics closed at $8.30 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
- Goldman Sachs Resumes Luxshare Precision (002475:CH) at Buy
- Citi Resumes Universal Music Group NV (UMG:NA) (UMGNF) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
Morgan JosephSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
